We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simultaneous Treatment of Multiple Metabolic Pathways Better at Blocking Brain Tumor Growth

By LabMedica International staff writers
Posted on 27 Jan 2011
Chemotherapy directed at two or more of the embryonic metabolic pathways active in brain tumors was significantly more effective in blocking tumor growth than was inhibition of any single pathway.

Multiple early developmental pathways including Notch, Hedgehog, and Wnt function in malignant brain tumors such as medulloblastoma and glioblastoma (GBM). More...
This fact raises the possibility that tumors might compensate for therapy directed against one pathway by upregulating a different one.

Investigators at Johns Hopkins University (Baltimore, MD, USA) carried out experiments designed to determine whether brain tumors show resistance to therapies against Notch, and whether targeting multiple pathways simultaneously would kill brain tumor cells more effectively than monotherapy. To this end, they worked with clusters of GBM cells growing in culture (neurospheres) and with fresh sample of cancerous tissue obtained from patients.

They reported in the December 15, 2010, issue of the journal Clinical Cancer Research that GBM cells were at least partially resistant to long-term treatment with the gamma-secretase Notch suppressor MRK-003. Blocking the Notch pathway in neurospheres caused increased activity in both the Hedgehog and Wnt pathways. Targeting Notch and Hedgehog simultaneously induced apoptosis, decreased cell growth, and inhibited colony-forming ability more dramatically than monotherapy.

Dual treatment of fresh glioblastoma samples with Notch and Hedgehog inhibitors decreased by 50% to 80% the number of colonies formed in culture and decreased the average size of neurospheres.

"Our study indicates it may be necessary to simultaneously target multiple development signaling pathways to prevent cancers from becoming resistant to therapy,” said senior author Dr. Charles Eberhart, associate professor of pathology, ophthalmology, and oncology at Johns Hopkins University. "A single agent is not likely to work for prolonged periods.”

"Clinical trials evaluating inhibitors of Hedgehog or Notch in a number of cancer types are currently under way at Johns Hopkins University and several other sites across the country, said Dr. Eberhart.” Further studies will examine the relationship among the Notch, Hedgehog, and Wnt pathways in glioblastoma and look for other signaling processes that help tumors become resistant to therapy.”

Related Links:

Johns Hopkins University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.